Henlius Wins NMPA Nod for Novel Lung Cancer Combination Trial

Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.

Shanghai Henlius Biotech has secured Chinese regulatory approval to begin clinical trials of its investigational EGFR-targeting antibody pimurutamab HLX07 combined with its marketed PD-1 inhibitor HANSIZHUANG and chemotherapy in patients with advanced squamous non-small cell lung cancer. HLX07 has previously shown a favorable safety profile in early-stage studies and is already being evaluated in several Phase 2 trials across solid tumors, while HANSIZHUANG is approved in China and multiple international markets for several cancer indications.

The new trial targets a treatment combination that, according to the company, has not yet been approved anywhere globally, underscoring Henlius’s bid to differentiate its oncology pipeline in a crowded immunotherapy field. Successful development could strengthen the company’s position in lung cancer therapeutics and broaden commercial potential for both HLX07 and HANSIZHUANG, though Henlius cautions that there is no guarantee the program will ultimately reach the market.

The most recent analyst rating on (HK:2696) stock is a Hold with a HK$64.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.

More about Shanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. is a China-based biopharmaceutical company specializing in innovative biologic drugs, particularly monoclonal antibodies for oncology and immunology. Its flagship product HANSIZHUANG (serplulimab) is an anti-PD-1 therapy already approved in mainland China and multiple overseas markets for various lung, esophageal and other cancers, with a growing global clinical portfolio.

Average Trading Volume: 974,925

Technical Sentiment Signal: Strong Buy

Current Market Cap: HK$24.14B

For detailed information about 2696 stock, go to TipRanks’ Stock Analysis page.